Two of the most talked-about health-tech companies are apparently joining forces. Neko Health and Neuralink are collaborating on a survey that leverages Neko’s body-scan data to screen potential candidates for Neuralink’s clinical trials, according to a social media announcement.
What Neko brings to the table
Neko Health has built a business around preventive health monitoring through advanced full-body scans. Each one-hour session uses proprietary sensors to assess skin health, cardiovascular function, and a range of other biological metrics, generating millions of individual data points per patient.
The service is priced at $499 in the US market, where the company is actively expanding. Neko raised $700 million in its Series C funding round, which closed on July 15, 2026, specifically to fuel its push into the US. Its first American clinic is scheduled to open in New York City on September 24, 2026.
Neuralink’s screening problem
Neuralink’s PRIME Study, its flagship clinical trial, targets patients with quadriplegia resulting from spinal cord injuries or amyotrophic lateral sclerosis (ALS). The eligibility criteria are narrow, the medical stakes are enormous, and the consequences of implanting a device in the wrong patient could be severe.
By running consented body-scan data through an eligibility survey, the collaboration could potentially pre-screen candidates before they ever step into a neurosurgery clinic. A comprehensive health snapshot, captured in a single session, might flag disqualifying conditions or confirm baseline health requirements far earlier in the pipeline.
The consent question and practical unknowns
The arrangement reportedly involves consented body-scan data, meaning Neko Health users would need to actively opt into having their information used for Neuralink screening purposes. The mechanics of that consent process remain unclear.
There is also the question of how useful Neko’s data actually is for Neuralink’s specific needs. Neko’s scans focus on skin, cardiovascular health, and general biological metrics. Neuralink’s PRIME Study requires candidates with very specific neurological conditions. Confirming a spinal cord injury diagnosis or ALS staging typically requires specialized neurological evaluation. Neko’s scans may serve as a first-pass filter, helping rule out candidates with disqualifying cardiovascular conditions or other systemic health issues before more targeted neurological screening begins.
No formal partnership between the two companies has been officially confirmed through traditional channels as of August 23, 2026. The collaboration surfaced through social media.